| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arsenic | 56 | 2025 | 272 | 10.280 |
Why?
|
| Environmental Exposure | 35 | 2025 | 355 | 4.810 |
Why?
|
| Water Pollutants, Chemical | 23 | 2022 | 140 | 3.530 |
Why?
|
| Bangladesh | 57 | 2025 | 339 | 2.820 |
Why?
|
| Arsenic Poisoning | 15 | 2019 | 104 | 2.720 |
Why?
|
| Environmental Pollutants | 7 | 2022 | 56 | 2.070 |
Why?
|
| Metals | 6 | 2025 | 102 | 2.060 |
Why?
|
| Oryza | 5 | 2021 | 44 | 1.610 |
Why?
|
| DNA Methylation | 10 | 2025 | 697 | 1.580 |
Why?
|
| Drinking Water | 10 | 2022 | 70 | 1.520 |
Why?
|
| Maternal Exposure | 6 | 2021 | 63 | 1.510 |
Why?
|
| Diet | 8 | 2019 | 460 | 1.370 |
Why?
|
| Skin Diseases | 13 | 2019 | 174 | 1.370 |
Why?
|
| Telomere | 5 | 2025 | 120 | 1.350 |
Why?
|
| Genetic Predisposition to Disease | 16 | 2025 | 2465 | 1.240 |
Why?
|
| Female | 100 | 2025 | 48708 | 1.210 |
Why?
|
| Polymorphism, Single Nucleotide | 21 | 2021 | 2484 | 1.150 |
Why?
|
| Middle Aged | 81 | 2025 | 27580 | 1.150 |
Why?
|
| Adult | 79 | 2025 | 27921 | 1.060 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2021 | 176 | 1.060 |
Why?
|
| Cohort Studies | 24 | 2023 | 3056 | 1.060 |
Why?
|
| Male | 87 | 2025 | 44564 | 1.050 |
Why?
|
| Humans | 124 | 2025 | 93522 | 1.020 |
Why?
|
| Gene-Environment Interaction | 5 | 2025 | 120 | 1.010 |
Why?
|
| Pregnancy Outcome | 2 | 2020 | 268 | 1.010 |
Why?
|
| Blood Pressure | 8 | 2020 | 896 | 1.000 |
Why?
|
| Water Supply | 12 | 2022 | 66 | 1.000 |
Why?
|
| Cacodylic Acid | 4 | 2021 | 22 | 0.980 |
Why?
|
| Nutrition Surveys | 7 | 2022 | 125 | 0.950 |
Why?
|
| Lung | 4 | 2021 | 1366 | 0.940 |
Why?
|
| Vital Capacity | 4 | 2021 | 73 | 0.930 |
Why?
|
| Epigenesis, Genetic | 5 | 2025 | 555 | 0.910 |
Why?
|
| Heart Diseases | 3 | 2025 | 257 | 0.890 |
Why?
|
| Groundwater | 2 | 2022 | 14 | 0.890 |
Why?
|
| Skin Neoplasms | 7 | 2025 | 620 | 0.890 |
Why?
|
| Multifactorial Inheritance | 2 | 2025 | 202 | 0.880 |
Why?
|
| Metals, Heavy | 3 | 2019 | 17 | 0.860 |
Why?
|
| Environmental Monitoring | 7 | 2024 | 89 | 0.850 |
Why?
|
| Aged | 50 | 2025 | 20439 | 0.810 |
Why?
|
| Asthma | 2 | 2021 | 1039 | 0.780 |
Why?
|
| Allostasis | 1 | 2023 | 2 | 0.770 |
Why?
|
| Cardiovascular Diseases | 9 | 2021 | 755 | 0.760 |
Why?
|
| Child | 13 | 2025 | 7355 | 0.760 |
Why?
|
| Occupational Exposure | 3 | 2018 | 87 | 0.730 |
Why?
|
| Hypertension | 5 | 2019 | 758 | 0.730 |
Why?
|
| Forced Expiratory Volume | 2 | 2021 | 136 | 0.720 |
Why?
|
| Longitudinal Studies | 21 | 2025 | 1161 | 0.670 |
Why?
|
| Risk Factors | 22 | 2025 | 5901 | 0.670 |
Why?
|
| Selenium | 3 | 2019 | 46 | 0.670 |
Why?
|
| Pesticides | 4 | 2020 | 30 | 0.660 |
Why?
|
| Prospective Studies | 25 | 2020 | 4562 | 0.660 |
Why?
|
| Gravidity | 1 | 2020 | 7 | 0.660 |
Why?
|
| Adolescent | 33 | 2024 | 9607 | 0.650 |
Why?
|
| Metabolic Syndrome | 2 | 2018 | 122 | 0.640 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2017 | 691 | 0.630 |
Why?
|
| Smoking | 8 | 2019 | 648 | 0.620 |
Why?
|
| Genome-Wide Association Study | 14 | 2021 | 1762 | 0.590 |
Why?
|
| Young Adult | 32 | 2023 | 6930 | 0.590 |
Why?
|
| Cardiotoxins | 1 | 2018 | 3 | 0.580 |
Why?
|
| Manganese | 1 | 2019 | 56 | 0.580 |
Why?
|
| Residence Characteristics | 1 | 2020 | 212 | 0.570 |
Why?
|
| Food | 3 | 2015 | 92 | 0.570 |
Why?
|
| Food Contamination | 5 | 2019 | 35 | 0.560 |
Why?
|
| Acculturation | 3 | 2024 | 16 | 0.560 |
Why?
|
| Pregnancy | 8 | 2022 | 3147 | 0.560 |
Why?
|
| United States | 16 | 2025 | 7622 | 0.550 |
Why?
|
| Cross-Sectional Studies | 10 | 2021 | 1847 | 0.550 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2024 | 1229 | 0.540 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 1 | 2017 | 17 | 0.530 |
Why?
|
| Child Mortality | 1 | 2017 | 9 | 0.530 |
Why?
|
| Urinalysis | 1 | 2017 | 34 | 0.520 |
Why?
|
| Obesity | 3 | 2021 | 1018 | 0.510 |
Why?
|
| Diet, Gluten-Free | 1 | 2017 | 60 | 0.500 |
Why?
|
| Birth Weight | 3 | 2022 | 150 | 0.490 |
Why?
|
| Arsenicals | 5 | 2019 | 49 | 0.480 |
Why?
|
| Antioxidants | 3 | 2013 | 231 | 0.470 |
Why?
|
| Carcinogens | 1 | 2016 | 101 | 0.470 |
Why?
|
| Mexican Americans | 3 | 2024 | 70 | 0.460 |
Why?
|
| Selenomethionine | 2 | 2013 | 11 | 0.460 |
Why?
|
| Proportional Hazards Models | 6 | 2020 | 889 | 0.460 |
Why?
|
| Lung Diseases | 2 | 2016 | 283 | 0.450 |
Why?
|
| Telomere Homeostasis | 3 | 2021 | 29 | 0.440 |
Why?
|
| Leukocytes | 3 | 2025 | 210 | 0.440 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 190 | 0.430 |
Why?
|
| Quantitative Trait Loci | 5 | 2021 | 630 | 0.420 |
Why?
|
| Gene Expression | 2 | 2018 | 1301 | 0.420 |
Why?
|
| Breast Neoplasms | 8 | 2019 | 3110 | 0.410 |
Why?
|
| Mendelian Randomization Analysis | 3 | 2021 | 50 | 0.410 |
Why?
|
| CpG Islands | 5 | 2019 | 168 | 0.410 |
Why?
|
| Public Health | 3 | 2022 | 153 | 0.410 |
Why?
|
| Transcriptome | 3 | 2025 | 762 | 0.400 |
Why?
|
| Water Wells | 4 | 2022 | 18 | 0.400 |
Why?
|
| Digestive System Neoplasms | 1 | 2013 | 20 | 0.390 |
Why?
|
| alpha-Tocopherol | 1 | 2013 | 9 | 0.390 |
Why?
|
| Body Mass Index | 9 | 2021 | 811 | 0.390 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 71 | 0.380 |
Why?
|
| Water Pollution, Chemical | 3 | 2011 | 21 | 0.360 |
Why?
|
| Aging | 4 | 2025 | 727 | 0.360 |
Why?
|
| Methyltransferases | 3 | 2019 | 213 | 0.360 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2025 | 1338 | 0.360 |
Why?
|
| Genome, Human | 5 | 2019 | 823 | 0.350 |
Why?
|
| Air Pollutants | 2 | 2024 | 108 | 0.330 |
Why?
|
| Child, Preschool | 4 | 2025 | 3829 | 0.320 |
Why?
|
| Vitamin B Complex | 1 | 2010 | 21 | 0.310 |
Why?
|
| Gene Expression Profiling | 6 | 2025 | 1518 | 0.310 |
Why?
|
| Neoplasms | 5 | 2023 | 3169 | 0.310 |
Why?
|
| Phenotype | 9 | 2024 | 2544 | 0.310 |
Why?
|
| Genotype | 8 | 2019 | 1866 | 0.310 |
Why?
|
| Ammonia-Lyases | 2 | 2019 | 6 | 0.300 |
Why?
|
| Glutamate Formimidoyltransferase | 2 | 2019 | 6 | 0.300 |
Why?
|
| Gestational Age | 2 | 2021 | 333 | 0.300 |
Why?
|
| Infant | 3 | 2021 | 3220 | 0.280 |
Why?
|
| Genotyping Techniques | 3 | 2019 | 71 | 0.280 |
Why?
|
| Loss of Heterozygosity | 1 | 2008 | 84 | 0.270 |
Why?
|
| Chicago | 3 | 2021 | 1464 | 0.270 |
Why?
|
| Infant, Newborn | 4 | 2020 | 2479 | 0.270 |
Why?
|
| Parity | 2 | 2020 | 97 | 0.270 |
Why?
|
| Gene Expression Regulation | 4 | 2018 | 1985 | 0.270 |
Why?
|
| Gene Amplification | 1 | 2008 | 140 | 0.270 |
Why?
|
| Biomarkers | 6 | 2024 | 1910 | 0.250 |
Why?
|
| Cadmium | 4 | 2024 | 29 | 0.250 |
Why?
|
| Odds Ratio | 6 | 2019 | 712 | 0.250 |
Why?
|
| Mortality | 3 | 2017 | 156 | 0.250 |
Why?
|
| Chromosome Aberrations | 1 | 2008 | 350 | 0.250 |
Why?
|
| Social Class | 1 | 2007 | 141 | 0.240 |
Why?
|
| Prevalence | 7 | 2018 | 1321 | 0.230 |
Why?
|
| Mercury | 1 | 2025 | 11 | 0.220 |
Why?
|
| Nails | 1 | 2025 | 11 | 0.220 |
Why?
|
| Volatile Organic Compounds | 1 | 2024 | 4 | 0.220 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 1775 | 0.220 |
Why?
|
| Silicones | 1 | 2024 | 21 | 0.220 |
Why?
|
| Wrist | 1 | 2024 | 29 | 0.220 |
Why?
|
| Genetic Research | 1 | 2024 | 18 | 0.220 |
Why?
|
| Sex Factors | 4 | 2018 | 1105 | 0.210 |
Why?
|
| Metabolomics | 1 | 2024 | 98 | 0.210 |
Why?
|
| Metabolome | 1 | 2024 | 62 | 0.210 |
Why?
|
| Lymphocytes | 1 | 2006 | 454 | 0.210 |
Why?
|
| Sequence Deletion | 1 | 2025 | 209 | 0.210 |
Why?
|
| Life Style | 3 | 2023 | 183 | 0.210 |
Why?
|
| Linear Models | 1 | 2025 | 413 | 0.200 |
Why?
|
| Smoking Cessation | 2 | 2019 | 269 | 0.200 |
Why?
|
| Sleep Wake Disorders | 1 | 2024 | 124 | 0.200 |
Why?
|
| Blood Glucose | 2 | 2024 | 867 | 0.200 |
Why?
|
| Apolipoprotein E4 | 1 | 2023 | 32 | 0.190 |
Why?
|
| Bayes Theorem | 1 | 2025 | 402 | 0.190 |
Why?
|
| Genetic Variation | 3 | 2018 | 1415 | 0.190 |
Why?
|
| Multifunctional Enzymes | 2 | 2019 | 7 | 0.190 |
Why?
|
| Precancerous Conditions | 3 | 2010 | 205 | 0.190 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 624 | 0.190 |
Why?
|
| United Kingdom | 1 | 2023 | 190 | 0.180 |
Why?
|
| Population Health | 1 | 2022 | 33 | 0.180 |
Why?
|
| Biological Specimen Banks | 1 | 2023 | 72 | 0.180 |
Why?
|
| Molybdenum | 1 | 2022 | 11 | 0.180 |
Why?
|
| Air Pollution | 2 | 2023 | 107 | 0.180 |
Why?
|
| Thinness | 2 | 2014 | 45 | 0.180 |
Why?
|
| Myocardial Infarction | 1 | 2025 | 385 | 0.180 |
Why?
|
| Respiration Disorders | 2 | 2013 | 42 | 0.180 |
Why?
|
| Copper | 1 | 2022 | 79 | 0.170 |
Why?
|
| Blood Cells | 1 | 2021 | 32 | 0.170 |
Why?
|
| Databases, Genetic | 3 | 2019 | 282 | 0.170 |
Why?
|
| Regression Analysis | 4 | 2017 | 579 | 0.170 |
Why?
|
| Telomere Shortening | 1 | 2021 | 25 | 0.170 |
Why?
|
| Incidence | 5 | 2018 | 1702 | 0.170 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2021 | 49 | 0.170 |
Why?
|
| Lead | 2 | 2024 | 32 | 0.160 |
Why?
|
| Biomarkers, Tumor | 4 | 2018 | 1660 | 0.160 |
Why?
|
| Sleep | 1 | 2024 | 448 | 0.160 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2023 | 49 | 0.160 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 190 | 0.160 |
Why?
|
| Water Purification | 1 | 2020 | 4 | 0.160 |
Why?
|
| beta-Globins | 1 | 2019 | 3 | 0.160 |
Why?
|
| Blood | 1 | 2019 | 68 | 0.150 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 304 | 0.150 |
Why?
|
| Insulin Resistance | 1 | 2022 | 379 | 0.150 |
Why?
|
| Case-Control Studies | 6 | 2018 | 1932 | 0.150 |
Why?
|
| Receptor, EphA4 | 1 | 2019 | 5 | 0.150 |
Why?
|
| Texas | 3 | 2024 | 131 | 0.150 |
Why?
|
| Whole Genome Sequencing | 1 | 2019 | 109 | 0.150 |
Why?
|
| Genes, Mitochondrial | 1 | 2018 | 11 | 0.150 |
Why?
|
| Receptors, Opioid | 1 | 2019 | 23 | 0.150 |
Why?
|
| Metabolism | 1 | 2018 | 24 | 0.140 |
Why?
|
| Ions | 1 | 2019 | 78 | 0.140 |
Why?
|
| Tobacco Smoking | 1 | 2019 | 31 | 0.140 |
Why?
|
| Genetic Testing | 1 | 2022 | 565 | 0.140 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 7063 | 0.140 |
Why?
|
| Muscle Contraction | 1 | 2019 | 256 | 0.140 |
Why?
|
| Exercise | 2 | 2021 | 353 | 0.140 |
Why?
|
| DNA, Mitochondrial | 1 | 2018 | 200 | 0.140 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2019 | 232 | 0.140 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 603 | 0.130 |
Why?
|
| Waist-Height Ratio | 1 | 2017 | 2 | 0.130 |
Why?
|
| Atlases as Topic | 1 | 2017 | 10 | 0.130 |
Why?
|
| Abortion, Therapeutic | 1 | 2017 | 11 | 0.130 |
Why?
|
| Stillbirth | 1 | 2017 | 14 | 0.130 |
Why?
|
| Naltrexone | 1 | 2019 | 139 | 0.130 |
Why?
|
| Solvents | 1 | 2017 | 91 | 0.130 |
Why?
|
| Epistasis, Genetic | 1 | 2018 | 90 | 0.130 |
Why?
|
| Dietary Exposure | 1 | 2017 | 2 | 0.130 |
Why?
|
| Chromosomes, Human | 1 | 2017 | 65 | 0.130 |
Why?
|
| Narcotic Antagonists | 1 | 2019 | 170 | 0.130 |
Why?
|
| DNA Helicases | 1 | 2017 | 89 | 0.130 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 2802 | 0.130 |
Why?
|
| Depressive Disorder | 1 | 2017 | 225 | 0.120 |
Why?
|
| Abortion, Spontaneous | 1 | 2017 | 73 | 0.120 |
Why?
|
| Mutation | 2 | 2024 | 4272 | 0.120 |
Why?
|
| Drinking | 3 | 2011 | 34 | 0.120 |
Why?
|
| Creatinine | 1 | 2017 | 293 | 0.120 |
Why?
|
| Age Factors | 2 | 2018 | 1906 | 0.120 |
Why?
|
| Health Surveys | 3 | 2023 | 241 | 0.120 |
Why?
|
| DNA Copy Number Variations | 1 | 2017 | 192 | 0.120 |
Why?
|
| Parents | 1 | 2018 | 292 | 0.120 |
Why?
|
| Areca | 2 | 2013 | 11 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 3832 | 0.110 |
Why?
|
| Precision Medicine | 1 | 2019 | 456 | 0.110 |
Why?
|
| Dyspnea | 1 | 2016 | 86 | 0.110 |
Why?
|
| Proteinuria | 1 | 2015 | 69 | 0.110 |
Why?
|
| Anxiety Disorders | 1 | 2016 | 155 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2013 | 1914 | 0.110 |
Why?
|
| Fetal Blood | 1 | 2015 | 95 | 0.110 |
Why?
|
| Mitochondria | 1 | 2018 | 612 | 0.110 |
Why?
|
| Developing Countries | 1 | 2015 | 91 | 0.110 |
Why?
|
| Illinois | 1 | 2016 | 520 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 105 | 0.100 |
Why?
|
| Phosphofructokinase-1, Muscle Type | 1 | 2014 | 9 | 0.100 |
Why?
|
| Chondromatosis | 1 | 1993 | 2 | 0.100 |
Why?
|
| Leiomyoma, Epithelioid | 1 | 1993 | 2 | 0.100 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 381 | 0.100 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 1993 | 11 | 0.100 |
Why?
|
| Arm | 1 | 2014 | 97 | 0.100 |
Why?
|
| Mediastinal Neoplasms | 1 | 1993 | 43 | 0.100 |
Why?
|
| Anxiety | 1 | 2016 | 337 | 0.100 |
Why?
|
| Depression | 1 | 2017 | 544 | 0.100 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1993 | 100 | 0.100 |
Why?
|
| Overweight | 1 | 2014 | 120 | 0.100 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 419 | 0.100 |
Why?
|
| Vitamin E | 2 | 2014 | 34 | 0.100 |
Why?
|
| Keratosis | 1 | 2012 | 21 | 0.090 |
Why?
|
| Urinary Bladder | 1 | 2015 | 260 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2016 | 585 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2015 | 457 | 0.090 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 317 | 0.090 |
Why?
|
| Alleles | 4 | 2019 | 1139 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2012 | 47 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2013 | 1729 | 0.090 |
Why?
|
| Tremor | 1 | 2011 | 22 | 0.080 |
Why?
|
| Essential Tremor | 1 | 2011 | 6 | 0.080 |
Why?
|
| Skin | 1 | 2014 | 578 | 0.080 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2015 | 378 | 0.080 |
Why?
|
| Methylation | 3 | 2019 | 288 | 0.080 |
Why?
|
| Tissue Fixation | 1 | 2010 | 39 | 0.080 |
Why?
|
| Formaldehyde | 1 | 2010 | 51 | 0.080 |
Why?
|
| Paraffin Embedding | 1 | 2010 | 77 | 0.080 |
Why?
|
| Stomach Neoplasms | 1 | 1993 | 308 | 0.080 |
Why?
|
| Thyroid Hormones | 2 | 2023 | 350 | 0.080 |
Why?
|
| Protective Agents | 1 | 2010 | 34 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2015 | 580 | 0.080 |
Why?
|
| Machine Learning | 2 | 2025 | 341 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2022 | 557 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2011 | 213 | 0.080 |
Why?
|
| Water | 1 | 2011 | 307 | 0.080 |
Why?
|
| DNA | 1 | 2014 | 1265 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2008 | 42 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2008 | 78 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2008 | 85 | 0.070 |
Why?
|
| Protein Carbonylation | 1 | 2008 | 10 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2008 | 102 | 0.070 |
Why?
|
| Gene Dosage | 1 | 2008 | 211 | 0.070 |
Why?
|
| Gene Frequency | 2 | 2019 | 700 | 0.070 |
Why?
|
| Sex Characteristics | 2 | 2019 | 333 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2010 | 960 | 0.060 |
Why?
|
| Ownership | 1 | 2007 | 28 | 0.060 |
Why?
|
| Rural Population | 3 | 2014 | 170 | 0.060 |
Why?
|
| Population Groups | 1 | 2006 | 42 | 0.060 |
Why?
|
| Cause of Death | 3 | 2013 | 273 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2018 | 2441 | 0.060 |
Why?
|
| Chromosome Mapping | 1 | 2008 | 1052 | 0.060 |
Why?
|
| Computer Simulation | 2 | 2022 | 1118 | 0.050 |
Why?
|
| Emigrants and Immigrants | 1 | 2025 | 46 | 0.050 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2024 | 63 | 0.050 |
Why?
|
| Demography | 2 | 2015 | 189 | 0.050 |
Why?
|
| Vegetables | 2 | 2015 | 50 | 0.050 |
Why?
|
| Postmenopause | 1 | 2023 | 106 | 0.050 |
Why?
|
| Age of Onset | 2 | 2017 | 342 | 0.050 |
Why?
|
| Particulate Matter | 1 | 2023 | 123 | 0.050 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2023 | 106 | 0.050 |
Why?
|
| Income | 1 | 2022 | 87 | 0.050 |
Why?
|
| Research Design | 1 | 2006 | 618 | 0.050 |
Why?
|
| Insulins | 1 | 2022 | 7 | 0.050 |
Why?
|
| Animals | 2 | 2019 | 28155 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 1993 | 2365 | 0.040 |
Why?
|
| Thyrotropin | 1 | 2022 | 309 | 0.040 |
Why?
|
| Accelerometry | 1 | 2021 | 48 | 0.040 |
Why?
|
| Triiodothyronine | 1 | 2022 | 361 | 0.040 |
Why?
|
| Michigan | 1 | 2020 | 55 | 0.040 |
Why?
|
| Thyroxine | 1 | 2022 | 386 | 0.040 |
Why?
|
| Waist-Hip Ratio | 1 | 2018 | 21 | 0.040 |
Why?
|
| Folic Acid | 1 | 2019 | 62 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2022 | 372 | 0.040 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2019 | 134 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2019 | 478 | 0.030 |
Why?
|
| Health Education | 1 | 2019 | 105 | 0.030 |
Why?
|
| Estrogens | 1 | 2019 | 195 | 0.030 |
Why?
|
| Obesity, Abdominal | 1 | 2017 | 8 | 0.030 |
Why?
|
| Glutathione Transferase | 1 | 2018 | 115 | 0.030 |
Why?
|
| Breast | 1 | 2019 | 294 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2024 | 1077 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 2017 | 83 | 0.030 |
Why?
|
| Adipocytes | 1 | 2018 | 169 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2019 | 297 | 0.030 |
Why?
|
| Adiposity | 1 | 2017 | 76 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2019 | 555 | 0.030 |
Why?
|
| Triglycerides | 1 | 2017 | 231 | 0.030 |
Why?
|
| Longevity | 1 | 2017 | 60 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2018 | 196 | 0.030 |
Why?
|
| Dyslipidemias | 1 | 2017 | 108 | 0.030 |
Why?
|
| Genetics, Population | 1 | 2019 | 439 | 0.030 |
Why?
|
| Time Factors | 2 | 2015 | 5412 | 0.030 |
Why?
|
| Computational Biology | 1 | 2019 | 578 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2018 | 413 | 0.030 |
Why?
|
| Self Report | 1 | 2017 | 328 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2024 | 10166 | 0.030 |
Why?
|
| Glucose | 1 | 2018 | 692 | 0.030 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2015 | 19 | 0.030 |
Why?
|
| Fruit | 1 | 2015 | 81 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2018 | 962 | 0.030 |
Why?
|
| Asia | 1 | 2014 | 107 | 0.030 |
Why?
|
| Data Collection | 2 | 2006 | 370 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 293 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2014 | 93 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 1007 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2015 | 147 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 296 | 0.030 |
Why?
|
| Insulin | 1 | 2018 | 1185 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 1524 | 0.030 |
Why?
|
| Poverty | 1 | 2015 | 193 | 0.030 |
Why?
|
| Causality | 1 | 2013 | 82 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2015 | 306 | 0.020 |
Why?
|
| Disease Progression | 1 | 2018 | 1531 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 876 | 0.020 |
Why?
|
| Spectrophotometry, Atomic | 1 | 2013 | 11 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 215 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2015 | 784 | 0.020 |
Why?
|
| Organ Size | 1 | 2014 | 362 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2013 | 155 | 0.020 |
Why?
|
| Inflammation | 1 | 2019 | 1050 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 572 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 887 | 0.020 |
Why?
|
| Syndrome | 1 | 1993 | 437 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2013 | 200 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2013 | 307 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 826 | 0.020 |
Why?
|
| Tobacco, Smokeless | 1 | 2011 | 10 | 0.020 |
Why?
|
| Genomics | 1 | 2018 | 848 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 767 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 3435 | 0.020 |
Why?
|
| Food Analysis | 1 | 2011 | 4 | 0.020 |
Why?
|
| Community Health Planning | 1 | 2011 | 22 | 0.020 |
Why?
|
| Cucurbitaceae | 1 | 2010 | 4 | 0.020 |
Why?
|
| Cell Movement | 1 | 2015 | 809 | 0.020 |
Why?
|
| Mastication | 1 | 2011 | 78 | 0.020 |
Why?
|
| Fertilizers | 1 | 2010 | 9 | 0.020 |
Why?
|
| Sunlight | 1 | 2010 | 27 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2010 | 39 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 302 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2011 | 364 | 0.020 |
Why?
|
| Prognosis | 1 | 2018 | 3912 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 60 | 0.020 |
Why?
|
| Epidemiological Monitoring | 1 | 2010 | 43 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2010 | 167 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2010 | 279 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 2850 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 391 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 524 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2015 | 2026 | 0.020 |
Why?
|
| Respiratory Tract Diseases | 1 | 2009 | 45 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 1741 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 884 | 0.020 |
Why?
|
| Intelligence | 1 | 2009 | 67 | 0.020 |
Why?
|
| Apoptosis | 1 | 2015 | 1721 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 3502 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2010 | 730 | 0.020 |
Why?
|
| Appendicitis | 1 | 1988 | 64 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2009 | 166 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2008 | 131 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2008 | 410 | 0.020 |
Why?
|
| Haplotypes | 1 | 2008 | 647 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2007 | 208 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 759 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2019 | 9103 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2008 | 917 | 0.010 |
Why?
|
| Proteins | 1 | 2010 | 803 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 1917 | 0.010 |
Why?
|
| Mice | 1 | 2019 | 12269 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 2715 | 0.010 |
Why?
|
| Risk | 1 | 2006 | 657 | 0.010 |
Why?
|
| RNA | 1 | 2007 | 573 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1988 | 59 | 0.000 |
Why?
|
| False Positive Reactions | 1 | 1988 | 212 | 0.000 |
Why?
|
| Acute Disease | 1 | 1988 | 841 | 0.000 |
Why?
|
| Ultrasonography | 1 | 1988 | 702 | 0.000 |
Why?
|